Educational Notice
Peptidings provides information for educational and research purposes only. The peptides discussed on this page are subjects of ongoing scientific research. None of the information presented here constitutes medical advice or a recommendation for use. Consult a qualified healthcare provider before making any decisions about peptide use.
Browse by Condition
Weight Loss
This is the most evidence-rich category on the site. Semaglutide, tirzepatide, and liraglutide are FDA-approved drugs with Phase III trial programs involving tens of thousands of participants—a standard of evidence that no other peptide category comes close to matching. Retatrutide and cagrisema are in late-stage clinical trials with compelling efficacy data. At the other end of the spectrum, compounds like 5-Amino-1MQ have no human trial data at all. The range within this single category illustrates exactly why evidence tier matters.
Approved Drug
Clinical Trials
Pilot / Human Data
Preclinical Only
It’s Complicated
Compounds with Research Relevant to Weight Loss
Each compound links to its full pillar article. The most useful sections for evaluating a specific application are the Claims vs. Evidence table and the Safety, Risks, and Limitations section. Evidence tiers reflect the strongest available data for a compound overall—not necessarily for this specific application.
5-Amino-1MQ: What the Research Shows
NNMT-inhibiting small molecule studied for fat loss and metabolic improvement. Preclinical evidence only.
Read the research →
AOD-9604: The Growth Hormone Fragment That Failed Its Only Clinical Trial
hGH fragment 176-191. Phase IIb oral trial (n=300) failed primary endpoint—no significant weight loss vs placebo. GRAS for food ingredient use is not drug approval.
Read the research →
CagriSema: What the Research Shows
Combination GLP-1/amylin receptor agonist studied for weight loss and glucose control. Phase III trials ongoing.
Read the research →
WADA
Liraglutide (Victoza / Saxenda): What the Research Shows
FDA-approved GLP-1 receptor agonist for type 2 diabetes and obesity. Extensive clinical trial evidence.
Read the research →
MOTS-c: The Mitochondrial Peptide That Tells Your Cells to Burn
Mitochondrial-derived peptide activating AMPK-mediated metabolic regulation. Exercise mimetic in rodent models. No human clinical trials for exogenous use.
Read the research →
Orforglipron: What the Research Shows
Oral non-peptide GLP-1 receptor agonist studied for weight loss and glucose control. Phase III trials ongoing.
Read the research →
Retatrutide: What the Research Shows
Triple GLP-1R/GIPR/GcgR agonist studied for weight loss, showing the largest reductions in Phase II trials to date.
Read the research →
WADA
Semaglutide (Ozempic / Wegovy): What the Research Shows
FDA-approved GLP-1 receptor agonist for type 2 diabetes and obesity. Available as Ozempic and Wegovy.
Read the research →
Survodutide: What the Research Shows
Dual GLP-1R/GcgR agonist studied for weight loss and NASH. Phase II/III trials ongoing.
Read the research →
Tesamorelin (Egrifta): What the Research Shows
FDA-approved GHRH analog (Egrifta) for HIV-associated lipodystrophy. Established clinical evidence.
Read the research →
WADA
Tirzepatide (Mounjaro / Zepbound): What the Research Shows
FDA-approved dual GLP-1R/GIPR agonist for type 2 diabetes and obesity. Available as Mounjaro and Zepbound.
Read the research →
Guides Relevant to This Condition
How to Reconstitute Lyophilized Peptides
Bacteriostatic water, reconstitution ratios, vial handling
FDA Regulatory Explainer
Category 1, 2, and 3 compounds—what the classifications mean for research use
Peptide Injection Technique Guide
Subcutaneous and intramuscular injection, site rotation, safety
Research Cluster
These compounds are covered in depth in the Weight Loss and Metabolic Peptides cluster hub.
Disclaimer: This page is for educational and research purposes only. It does not constitute medical advice, diagnosis, or treatment. The compounds discussed have not been evaluated by the FDA for all applications described. Consult a qualified healthcare provider before making any decisions about your health.